A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Summary

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

Timeline

Start

2020-08-19

Primary completion

2024-02-06

Completion

2024-02-06

Outcome

Outcome not reported

Stopped (Enrollment): “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

Publications

• Johansson MU, Kerschenmeyer A, Carella A, Carnal S, Schmidt Y, de Felice A, Mahler D, Thomas M, Spiga FM, Tietz J, Weinert C, Hess C, Urech D, Warmuth S. Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies. MAbs. 2026 Dec;18(1):2604353. doi: 10.1080/19420862.2025.2604353. Epub 2025 Dec 22.

Drugs

Indications